Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Refining the predictors of risk for central nervous system involvement in patients with mantle cell lymphoma.

Cheah CY, Seymour JF.

Leuk Lymphoma. 2013 Sep;54(9):1859-61. doi: 10.3109/10428194.2013.777839. No abstract available.

PMID:
23432685
2.

Secondary central nervous system involvement in cyclin D1-negative mantle cell lymphoma.

Dierickx D, Wlodarska I, Vanhentenrijk V, De Wolf-Peeters C, Devos T, Delforge M, Janssens A, Maertens J, Thomas J, Verhoef G.

Leuk Lymphoma. 2008 Dec;49(12):2365-6. doi: 10.1080/10428190802464737. No abstract available.

PMID:
19052986
3.

Central nervous system prophylaxis in mantle cell lymphoma.

Gatt ME, Grisaro S.

Blood. 2009 Dec 17;114(26):5402-3; author reply 5403-4. doi: 10.1182/blood-2009-09-245027. No abstract available.

4.

Risk factors of central nervous system relapse in mantle cell lymphoma.

Conconi A, Franceschetti S, Lobetti-Bodoni C, Stathis A, Margiotta-Casaluci G, Ramponi A, Mazzucchelli L, Bertoni F, Ghielmini M, Gaidano G, Cavalli F, Zucca E.

Leuk Lymphoma. 2013 Sep;54(9):1908-14. doi: 10.3109/10428194.2013.767454.

PMID:
23339449
5.

What is the real risk of central nervous system involvement in mantle cell lymphoma?

Gill S, Seymour JF.

Leuk Lymphoma. 2008 Dec;49(12):2237-9. doi: 10.1080/10428190802495855. No abstract available.

PMID:
19052969
6.

Central nervous system relapse in a patient with mantle cell lymphoma in continuous clinical and molecular remission at six years since autografting.

Ladetto M, Sametti S, Astolfi M, Corradini P, Ricca I, Drandi D, Pileri A, Tarella C.

Leuk Lymphoma. 2001 Feb;40(5-6):679-82.

PMID:
11426542
7.

Mantle cell lymphoma with central nervous system involvement: frequency and clinical features.

Gill S, Herbert KE, Prince HM, Wolf MM, Wirth A, Ryan G, Carney DA, Ritchie DS, Davies JM, Seymour JF.

Br J Haematol. 2009 Oct;147(1):83-8. doi: 10.1111/j.1365-2141.2009.07835.x.

PMID:
19694718
8.

Cerebrospinal fluid involvement in mantle cell lymphoma.

Valdez R, Kroft SH, Ross CW, Schnitzer B, Singleton TP, Peterson LC, Finn WG.

Mod Pathol. 2002 Oct;15(10):1073-9.

9.

Central nervous system involvement in intravascular large B-cell lymphoma: a retrospective analysis of 109 patients.

Shimada K, Murase T, Matsue K, Okamoto M, Ichikawa N, Tsukamoto N, Niitsu N, Miwa H, Asaoku H, Kosugi H, Kikuchi A, Matsumoto M, Saburi Y, Masaki Y, Yamamoto K, Yamaguchi M, Nakamura S, Naoe T, Kinoshita T; IVL Study Group in Japan..

Cancer Sci. 2010 Jun;101(6):1480-6. doi: 10.1111/j.1349-7006.2010.01555.x.

10.

Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation--an International Primary Central Nervous System Lymphoma Study Group project.

Bromberg JE, Doorduijn JK, Illerhaus G, Jahnke K, Korfel A, Fischer L, Fritsch K, Kuittinen O, Issa S, van Montfort C, van den Bent MJ.

Haematologica. 2013 May;98(5):808-13. doi: 10.3324/haematol.2012.070839.

11.

Local recurrence of primary central nervous system lymphoma due to tumor seeding.

Madkhali I, Bakshi N, Akhtar S, Maghfoor I.

Ann Saudi Med. 2013 May-Jun;33(3):310-1. doi: 10.5144/0256-4947.2013.310. No abstract available.

PMID:
23793439
12.

Lenalidomide for aggressive B-cell lymphoma involving the central nervous system?

Cox MC, Mannino G, Lionetto L, Naso V, Simmaco M, Spiriti MA.

Am J Hematol. 2011 Nov;86(11):957. doi: 10.1002/ajh.22148. No abstract available.

13.

High-dose chemotherapy and autologous stem cell transplantation for secondary central nervous system lymphoma: many are called, but few are chosen.

Abramson JS.

Haematologica. 2013 May;98(5):662-4. doi: 10.3324/haematol.2013.084285. No abstract available.

14.

[Treatment strategy for central nervous system involvement in intravascular large B-cell lymphoma].

Shimada K.

Brain Nerve. 2011 May;63(5):467-72. Review. Japanese.

PMID:
21515926
15.

Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma.

van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, Forman A, Romaguera J, Hagemeister F, Younes A, Bachier C, Sarris A, Sobocinski KS, Cox JD, Cabanillas F.

Blood. 1998 Feb 15;91(4):1178-84.

16.

Mantle cell lymphoma of the iris.

Economou MA, Kopp ED, All-Ericsson C, Seregard S.

Acta Ophthalmol Scand. 2007 May;85(3):341-3. No abstract available.

17.

Central nervous system prophylaxis in peripheral T-cell lymphoma.

Pro B, Perini G.

Blood. 2010 Jul 1;115(26):5427. doi: 10.1182/blood-2010-02-266890. No abstract available.

18.
19.

Secondary central nervous system lymphoma: risk factors and prophylaxis.

Montoto S, Lister TA.

Hematol Oncol Clin North Am. 2005 Aug;19(4):751-63, viii. Review.

PMID:
16083835
20.

Mantle cell lymphoma presenting with unusual morphology in an adolescent female: a case report and review of the literature.

Smock KJ, Yaish HM, Cairo MS, Lones MA, Willmore-Payne C, Perkins SL.

Pediatr Dev Pathol. 2007 Sep-Oct;10(5):403-8.

PMID:
17929987
Items per page

Supplemental Content

Support Center